Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium - Episode 1

Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

,

Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.

Now Viewing
EP. 1: Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)
EP. 2: Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC
EP. 3: Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC
EP. 4: Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment
EP. 5: Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial
EP. 6: Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment
EP. 7: COSMIC-313: Frontline Triplet Therapy in Advanced RCC
EP. 8: Emerging Data in Non-Clear Cell RCC Treatment
EP. 9: Exciting Investigational Therapies in Advanced RCC